Mesenchymal Stem Cell Therapy for Treatment of Craniofacial Bone Defects: 10 Years of Experience by Khojasteh, Arash & Motamedian, Saeed Reza
Regeneration, Reconstruction & Restoration                                                                                                          Regeneration 
Regeneration, Reconstruction & Restoration 2016;1(1): 1-7 
Mesenchymal Stem Cell Therapy for Treatment of Craniofacial Bone 
Defects: 10 Years of Experience 
Arash Khojasteh a*, Saeed Reza Motamedian b 
a Department of Oral and Maxillofacial Surgery, Dental Research Center, Research Institute of Dental Sciences, Dental School, Shahid Beheshti University of 
Medical Sciences, Tehran, Iran; b Department of Orthodontics, Dental School, Shahid Beheshti University of Medical Sciences, Tehran, Iran. 
*Corresponding author: Arash Khojasteh, Department of Oral and Maxillofacial Surgery, Dental School, Shahid Beheshti University of Medical Science, Daneshjou 
Boulevard, Evin, Tehran, Iran, P.O. 19839. E-mail: arashkhojasteh@sbmu.ac.ir; Tel: +98-21 88507687  
Submitted: 2015-08-24; Accepted: 2015-10-22; DOI: 10.7508/rrr.2016.01.001 
Introduction: Cell delivery in treatment of bone defects has been introduced to promote tissue healing in the recent years. However, no 
general consensus has been reached regarding the outcome of regenerative medicine for this purpose. The aim of this study was to review 
our 10 years of experience in application of mesenchymal stem cells (MSCs) in craniofacial bone defects. Applied Methodology: Iliac 
bone marrow, dental pulp and buccal fat pad were selected to harvest MSCs. Flow cytometric analysis, RT-PCR and differentiation 
staining including Alizarin red, Oil Red O and Toluidine blue were used to identify MSCs. Four groups of bone substitutes were used for 
cell delivery: synthetic scaffold [beta-tricalcium phosphate (B-TCP) and hydroxyapatite/tricalcium phosphate (HA/TCP)], xenograft 
[natural bovine bone mineral (NBBM)], allograft [freeze-dried bone (FDBA), demineralized freeze dried bone] and composite 
[polycaprolactone/TCP (PCL-TCP), demineralized freeze-dried bone/calcium sulfate]. Rat and rabbit calvaria, dog mandible, rabbit tibia 
sinus and alveolar cleft defects in human were used as the study models. Histomorphometric and radiomorphological analysis were used 
to determine new bone formation. Outcomes: Cell-treated groups showed greater new bone formation than cell-free group in all studies. 
Synthetic scaffolds showed better cell attachment according to scanning electron microscopy (SEM) results. In rat calvarial model, B-TCP 
loaded with MSCs showed better results than scaffolds carrying platelet rich plasma (PRP). NBBM showed less promising results both in 
dog mandible and ectopic bone formation in the masseter muscle. FDBA block fixed over a supracrestal defect in dog mandible showed 
50% less new bone formation when compared with PCL-TCP as a carrier. Conclusion: More convergence studies with similar protocols 
of cell cultivation, culture, seeding and delivery should be done in the field of regenerative medicine for better generalizability of results 
for clinical setting. 
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Introduction 
Bone as a highly differentiated tissue in the body may suffer 
defects due to congenital diseases, trauma, tumors and senile 
atrophy. Despite many advances in bone regeneration, 
reconstruction of large bony defects continues to be beyond the 
reach. Despite the availability of a plethora of treatment 
modalities, bone substitutes and various clinical adjuncts, most 
clinicians and researchers continue to reach the same 
conclusion. Autogenous bone grafts are still the “gold 
standard” to which all other reconstructive procedures are 
compared. However, autogenous bone grafts have several 
significant limitations, namely limited availability of competent 
sites and inherent donor site morbidity (1-4). Over the past few 
decades, considerable advancements have been made in tissue 
and bone engineering procedures. Bone engineering 
procedures apply osteogenic cells, growth factors and scaffolds 
to promote bone formation. Various osteogenic cells, including 
mesenchymal stem cells (MSCs) can be used in bone 
engineering protocols. MSCs have been proven to have 
proliferation and osteogenic differentiation capacities (5-8). 
Similarly, previous studies have demonstrated that MSC-based 
bone augmentation procedures induce higher levels of bone 
formation compared to acellular treatments (9-12). In addition, 
co-transplantation of growth factors in these procedures might 
further promote bone regeneration (13-15). The purpose of 
this study is to review our 10 years of experience in application 
of MSCs in craniofacial bone defects. 
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Applied Methodology 
Harvesting the MSCs  
Iliac bone marrow aspirate  
Two weeks before regenerative surgery, bone marrow aspirate 
(10-15 mL) was obtained from the posterior iliac crest. The 
aspirate was diluted at 1:3 in Dulbecco’s modified Eagle’s 
medium (DMEM)/F12 (Gibco, Paisley, UK). On day one, non-
adherent cells were discarded and adherent cells were washed 
with phosphate-buffered saline (PBS) (Gibco, Paisley, UK) and 
then cultured in DMEM/F12 with antibiotics and 20% 
autologous serum. 
Dental pulp 
Vital third molars of a healthy adult subject indicated for 
extraction were extracted. Before extraction, the patient was 
asked to rinse 0.2% chlorhexidine mouthwash (Behsa® Co., 
Tehran, Iran) for one minute. After extraction, the teeth were 
immersed in saline solution containing antibiotics. The crown of 
each tooth was cut into several segments and the pulp was 
exposed. Dental pulp tissue was removed with a barbed broach. 
Dissected tissue was minced and incubated in 3 mg/mL type I 
collagenase and 4 mg/mL dispase in PBS (Gibco, Paisley, UK) at 
37°C for 30 minutes. Then, the tissue fragments were immersed 
in α-MEM supplemented with 10% fetal bovine serum (FBS) and 
1% antibiotics (Gibco, Paisley, UK) and placed in 25 cm2 flasks. 
Flasks were incubated in humidified atmosphere with 5% CO2 at 
37°C. Culture medium was changed twice a week and after 
reaching the sub-confluent stage, the cells were removed by 
enzymatic digestion (0.25% trypsin–EDTA) and passaged. Third 
to fourth passage dental pulp stem cells (DPSCs) were subjected 
to the following experiments.  
Buccal fat pad  
Buccal fat pad was harvested from healthy donors via a vestibular 
incision distal to the maxillary second molar. The fat pad was 
exposed using blunt dissection while preserving the thin 
covering membrane; 3-5 mL of the fat was excised and 
transferred to a laboratory in DMEM. The tissue processing and 
cultivation of stem cells were done similar to the methods done 
for dental pulp. Adherent cells were expanded as monolayer 
cultures in 5% CO2/ 95% air atmosphere at 37°C; the medium 
was refreshed every three days. The confluent cells were 
dissociated with trypsin and sub-cultured in new six-well culture 
dishes at a plating density of 6×104 cells/dish. The cells were 
visible under light microscopy. The cells were stained with 
Trypan blue (1:1; v/v) and counted in a counting chamber using 
a light microscope (Nikon, Tokyo, Japan).  
Preparation of human serum 
In human trials, human serum was used for cultivation of the 
cells. From each donor bone marrow, 20 mL of whole blood was 
collected in blood bags and quickly transferred into 10-mL 
vacutainer tubes without anticoagulants (BD, Plymouth, UK), 
and allowed to clot for 4 hours at 4°C to 8°C. Subsequently, the 
blood was centrifuged at 1800g at 4°C for 15 minutes. Serum was 
collected and filtered through a 0.2 mm membrane. 
Identification of MSCs 
Flow cytometry analysis 
Fluorescence-activated cell sorting (FACS) was performed using 
standard protocols and quantification criteria. The criteria to 
distinguish positive from negative cells were set individually for 
each marker. Fluorescein isothiocyanate (FITC) conjugated 
monoclonal antibodies against CD34 (Miltenyi Biotech, Bergisch 
Gladbach, Germany), CD44, CD29, CD105 and CD13 (BD 
Biosciences, San Diego, CA, USA) at a concentration of 2 mg/mL 
at 4°C were used for 30 minutes. The cells stained with FITC-
labeled mouse IgG were used as negative controls. The cells were 
washed twice with PBS and fixed with 1% para-formaldehyde. 
Analysis was performed on 100,000 cells per sample and the 
positive expression was defined as the level of fluorescence 
greater than 99% of the corresponding value for unstained cell 
sample (11-14).  
Differentiation Staining  
Alizarin Red staining (osteogenic differentiation) 
To induce osteogenic differentiation, cells from third passage 
were provided with DMEM medium supplemented with 50 
mg/ml ascorbic 2-phosphate (Sigma Aldrich, St. Louis, MO, 
USA), 10 nM dexamethasone (Sigma Aldrich, St. Louis, MO, 
USA) and 10 mM glycerol phosphate (Sigma Aldrich, St. Louis, 
MO, USA). After 3 weeks, differentiated cells were fixed for 1 h 
with 4% formalin and rinsed with PBS (Gibco, Paisley, UK). 
Mineralization of the extracellular matrix was visualized by 
staining with 40 mM Alizarin Red S at a pH of 4.2 for 5 minutes.  
Oil Red staining (adipogenic differentiation) 
To induce adipose differentiation, third passage confluent cells 
were treated with a medium containing 100nM dexamethasone 
(Sigma Aldrich, St. Louis, MO, USA) and 50 mg/mL 
indomethacin (Sigma Aldrich, St. Louis, MO, USA). After three 
weeks, the cells were fixed with 4% formalin at room 
temperature, washed with 70% ethanol and stained with Oil Red 
solution in 99% isopropanol for 15 minutes. 
Toluidine blue staining (chondrogenic differentiation) 
To induce cartilage differentiation, micro-mass culture system 
was used. For this purpose, 2.5×105 third passage cells were  
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Table 1. Gene expression determined by RT-PCR for determination 
of differentiation potential of MSCs 
Cell lineage Genes 
Osteogenic differentiation Osteopontin, Collagen I 
Chondrogenic differentiation Decorin, Collagen II 
Adipogenic differentiation LPL, PPARG2 
pelleted under 1200 g for 5 minutes and cultured in DMEM 
supplemented with 10ng/mL transforming growth factor-ß3 
(TGFß3; Sigma Aldrich, St. Louis, MO, USA ), 10 ng/mL bone 
morphogenetic protein-6 (BMP-6; Sigma Aldrich, St. Louis, MO, 
USA), 50 mg/mL insulin transferrin selenium+ premix (Sigma 
Aldrich, St. Louis, MO, USA), 1.25 mg bovine serum albumin 
(BSA; Sigma Aldrich, St. Louis, MO, USA) and 1% FBS (Sigma 
Aldrich, St. Louis, MO, USA). After three weeks, the pellets were 
sectioned at 5 μm, stained with toluidine blue for 30 seconds at 
room temperature and observed under a light microscope. 
RT-PCR for gene expression 
The differentiation ability of the cells and some specific gene 
expressions were also studied by RT-PCR. For this purpose, total 
RNA was collected from the cells differentiated into bone, 
cartilage and adipose cells (as detailed above) using RNX-
PlusTM solution (CinnaGen Inc., Tehran, Iran). Before the 
reverse transcription, the RNA samples were digested with 
DNase I (Fermentas, Waltham, Massachusetts, USA) to remove 
the contaminating genomic DNA. Standard reverse-
transcription reaction was performed with 2μg total RNA using 
Random Hexamer as a primer and Revert Aid TM H Minus First 
Strand cDNA Synthesis Kit (Fermentas, Waltham, 
Massachusetts, USA) according to the manufacturer 
instructions. Subsequently, RT-PCR was performed using 2.5 μL 
cDNA, 1X PCR buffer (AMS), 200 μM dNTPs, 0.2 μM of each 
primer pair and 1 unit/25 μL reaction Taq DNA polymerase 
(Fermentas, Waltham, Massachusetts, USA). The primers 
indicated in Table 1 were used to detect differentiation. Each 
PCR was performed in triplicate. The products were analyzed on 
2% agarose gel and visualized by ethidium bromide staining. 
Cell Seeding 
A seeding concentration of 1.3×106 cells/mL was cultured on 
various bone grafts. Each layer of scaffold covering one of 24-
well plates was seeded with 2×105 MSCs in 200 μL of culture 
medium. The plates were incubated for 1 hour at 37°C 
allowing cell adhesion; then, half of the samples received 
1/500 of standard medium (containing α-MEM supplemented 
with 10% FBS, 1% antibiotic–antimycotic solution and 2 
mmol/L L- glutamine). We used different incubation times  
 
Figure 1. SEM micrograph of bone marrow MSCs attached to 
allograft scaffold porosities (×1000) 
for different types of bone substitutes Including synthetic 
scaffold [beta-tricalcium phosphate (B-TCP) and 
hydroxyapatite/tricalcium phosphate (HA/TCP)], xenograft 
[natural bovine bone mineral (NBBM)], allograft [freeze-dried 
bone (FDBA), demineralized freeze dried bone] and composite 
[polycaprolactone/TCP (PCL-TCP), demineralized freeze-dried 
bone/calcium sulfate ]. The bone substitutes were mixed with 
cells and incubated for at least 24 hours. We also tested 48 hours 
to 14 days of incubation in some of our experiments. Cell 
attachment was assessed by SEM.  
Scanning Electron Microscopy (SEM) 
Scaffold surface topography, adherent cell morphology and 
extracellular matrix culture were assessed using SEM. The seeded 
scaffolds were rinsed with PBS twice, fixed in 2.5% 
glutaraldehyde for two hours, and then post-fixed in 1% osmium 
for another two hours. Then, samples were dehydrated in graded 
concentrations of alcohol (30, 50, 70, 90, 95, and 100% ethanol). 
Afterwards, the samples were air dried in a desiccator overnight, 
sputtered with gold and observed under a SEM (VEGA, 
TESCAN, Brno-Kohoutovice, Czech Republic) at 10 kV. Images 
of non-seeded scaffolds were also taken. Moreover, the size of 
micro- and macro-porosities of each scaffold was measured by 
Image J 1.46 computer software (Wayne Rasband, NIH, 
Bethesda, Maryland, U.S.). 
Application of MSCs 
Bone substitutes mixed with MSCs were transferred to bone 
defects in different animal and human models (9-19). 
Histological and histomorphometric analyses were done after 
8-12 weeks according to the study protocols. 
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Figure 2. SEM micrographs of cultivation of DPSCs after one week over (A) allograft (freeze dried bone allograft) (×1000); (B) β- TCP (×1000) 
(C) xenograft (natural bovine bone mineral) (×1000) 
 
Outcomes  
The SEM analysis showed lodgment of cells within the pores of 
the scaffolds (Figure 1). By increasing the time of incubation to 
seven days, the number of attached cells also increased (20). 
Synthetic materials showed more attachment that the bovine or 
human-derived substitutes (Figure 2) (20). The in vivo results of 
our studies were analyzed based on the type of defect and carrier 
for MSCs (Table 2).  
Rat calvarial models   
Through-and-through 5 mm circular defects were created in rat 
calvarium. Rat bone marrow mesenchymal stem cells 
(BMMSCs) delivered by β-TCP or NBBM (Bio-Oss; Geistlich, 
Wolhusen, Switzerland) were compared with groups receiving 
PRP-soaked scaffolds. New bone formation was measured 
histomorphometrically. The maximum bone formation was 
reported to be 2.53 mm in the β-TCP/MSC group six weeks after 
the surgery (11).  
Rabbit models  
Rabbit calvarial model  
Two studies have been done on 8 mm rabbit calvarial defects.In 
the first experiment, MSCs were delivered by nano silica 
gel/hydroxyapatite (nanoHA) and new bone formation was 
measured histologically after six and 12 weeks post-surgery and 
in another one with the same protocol, MSCs were delivered by 
FDBA. In each study, there were four groups. Group 1: NanoHA 
granule; Group 2: Nano-HA+1 mL of autologous plasma rich in 
growth factors (PRGF); Group 3, Nano-HA+2 mL of culture 
medium containing 100,000 autogenous MSCs; Group 4, Nano-
HA + 2 mL of culture medium containing 100,000 autogenous 
MSCs +1 mL autologous PRGF. Histomorphometric analysis at 
six and 12 weeks demonstrated significantly higher bone 
formation in group 4 (29.45% and 44.55%, respectively). Bone 
formation in groups 1, 2, and 3 was as follows: 11.35% and 
32.53%, 29.10% and 39.74%, and 25.82% and 39.11%, 
respectively (14). In the second experiment, Nano-HA was 
replaced by FDBA. Histomorphometric analysis of the sections 
at six and 12 weeks post-operation demonstrated 14.6% and 
20.31% osteogenesis in group 1, 14.35% and 28.44% in group 2, 
17.75% and 31.33% in group 3 and 18.94% and 37.21% in group 
4, respectively (16). 
Rabbit tibial model 
We used rabbit tibia as a study model for delivery of MSCs. Right 
and left tibiae of each rabbit were prepared, and a 3-mm 
protruding implant from the tibia was placed in each side. 
Particulate allogeneic bone/fibrin glue/MSCs combination was 
placed around test implants and particulate bone graft/fibrin 
glue around controls. Two months postoperatively, the animals 
were euthanized, and sections were prepared for histological 
analysis. The mean amount of vertical bone height was higher in 
the experimental group than the control group (2.09 mm versus 
1.03 mm) (21).  
Dog models 
Ectopic bone formation 
For evaluation of ectopic bone formation, a blunt pouch in the 
masseter muscle of a dog was created, bone marrow derived 
MSCs were implanted over the HA/TCP (group 1) and NBBM 
(group 2). The results showed 29.12 and 23.55% of new bone 
formation, respectively (19).  
Mandibular defect in dogs 
The effectiveness of MSCs in treatment of mandibular defects of 
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dogs was studied in three experiments. Six weeks after delivering 
dog BMMSCs with biphasic scaffold (HA/TCP) or NBBM (Bio-
Oss) in a through-and-through 10-mm mandibular defect, new 
bone formation was reported to be 65.78% and 50.31%, 
respectively. The use of scaffolds without MSCs was accompanied 
by significantly lower bone regeneration (44.90% and 36.83%, 
respectively) (10). In another study we created a 10×20 mm 
supracrestal defect in the posterior mandible after extraction of the 
posterior teeth mimicking severe mandibular atrophy in 
edentulous patients. PCL-TCP block, which is a composite 
scaffold was used to carry the cells. The block was fixed with 1.2 mm 
micro screw (Jeil, Seoul, South Korea) to the underlying bone. 
Histomorphometric analysis eight weeks after scaffold implantation 
showed higher amount of lamellar bone in the test side (48.63%) 
than control side (17.27%) (17). In another study with the same 
protocol, freeze dried human derived bone block was used to deliver 
MSCs. Although in this study, MSCs were co-transplanted with 
recombinant platelet derived growth factor (rh-PDGF) the results 
showed only 21.52% of new bone formation (22). 
Human models  
We studied the application of MSCs in human subjects in three 
experiments. In the first study, we used HA-TCP loaded with 
BMMSCs in three cases of unilateral and four cases of bilateral 
sinus augmentation; dental implants were also placed in six 
patients, three months post-operatively. MSC-treated patients 
demonstrated adequate bone augmentation with 41.43% of new 
bone formation and an average bone height of 12 mm. These 
findings were based on histomorphometric and radiographic 
analyses three months after grafting. Radiographs 12 months 
postoperatively showed a 10.83-mm bone height increase. 
Twenty-eight of 30 implants (93%) were reported to be clinically 
successful at the six-month follow up (9).  
In the second study, demineralized bone matrix was combined 
with calcium sulfate (DBM/CaSO4) and BMMSCs for secondary 
repair of alveolar cleft in two patients. Panoramic radiographs of 
two cases of grafting of alveolar cleft using MSCs displayed 
adequate bone fill and union of the segmental arches. Four-month 
quantitative measurements by tomographic scans showed a bone 
fill of 34.5% for the first case and 25.6% for the second case (12). In 
the third trial, we added PRGF to HA/TCP loaded with MSCs to 
treat alveolar cleft defects in three patients. Cone beam computed 
tomography showed 52% of new bone formation (13). 
Discussion 
The use of cells for treatment of organ disorders is a traditional 
goal in regenerative medicine. Culturing cells in the lab and 
then differentiating them to specific cell lines to either produce 
tissue in the lab or cause tissue healing in situ has always been 
an ultimate goal for researchers. The problems against tissue 
formation outside the human body include nutritional supply 
of the cells and collecting their waste materials. Bioreactors 
are gradually going to find their place in tissue engineering 
(22, 23). Diversity among the study protocols such as cell 
cultivation and differentiation, cell seeding on scaffolds, 
incubation period and delivery methods can affect the efficacy 
of regenerative medicine in bone reconstruction. In a recent 
article we could not detect any common method utilized by 
tissue engineering studies (7). We performed cell harvesting, 
culture, differentiation, cell seeding on scaffolds and delivery 
to sites with the same techniques in our experiments in the 
past 10 years. Synthetic scaffolds such as TCP showed better 
results in comparison to NBBM in 6 mm rat calvarial defects 
when delivering MSCs. The same result was obtained when 
PRP was added to the scaffold (11). Biphasic synthetic 
HA/TCP demonstrated better results in regenerating new 
bone in the dog through and through 10 mm mandibular 
defect than NBBM (10). HA/TCP also had better cell 
attachment when compared to NBBM under SEM (11). In 
two human studies performed for treating alveolar cleft 
defects, MSCs co-transplanted with HA/TCP caused more 
bone formation than DBM/CaSO4 co- transplanted with 
MSCs (12, 13). FDBA showed less bone formation than nano-
HA with silica gel in 8 mm rabbit calvarial defects. FDBA and 
DFDBA showed the most promising results for cell 
attachments when investigated under SEM but in vivo studies 
showed different results. DFDBA loaded with MSCs was used 
around dental implants in rabbit tibia and revealed 2.1 mm 
vertical bone growth whereas no new bone formation was 
noted in the control cell-free group (21). FDBA as a block for 
treatment of posterior mandibular supracrestal defects in 
dogs was weaker in inducing new bone formation than PCL-
TCP scaffold (26.63% versus 48.63%) (22). In vitro evidence 
showed proper cell attachment to various scaffolds but in vivo 
application demonstrated better results when MSCs were 
delivered by synthetic substitutes (Table 2). 
Conclusion 
To the best of our knowledge, bone regenerative potential of 
cells delivered to the defect site is not comparable to 
autogenous bone grafting although they can enhance bone 
healing when applied to bone defects. Future studies with the 
same protocols of cell cultivation, culture, seeding and delivery 
should be done in the field of regenerative medicine to reach 
from bench to bedside. 
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